JP2014500250A5 - - Google Patents

Download PDF

Info

Publication number
JP2014500250A5
JP2014500250A5 JP2013537902A JP2013537902A JP2014500250A5 JP 2014500250 A5 JP2014500250 A5 JP 2014500250A5 JP 2013537902 A JP2013537902 A JP 2013537902A JP 2013537902 A JP2013537902 A JP 2013537902A JP 2014500250 A5 JP2014500250 A5 JP 2014500250A5
Authority
JP
Japan
Prior art keywords
poly
acetylglucosamine
composition according
deacetylated
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013537902A
Other languages
English (en)
Japanese (ja)
Other versions
JP6029591B2 (ja
JP2014500250A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/059558 external-priority patent/WO2012061803A2/en
Publication of JP2014500250A publication Critical patent/JP2014500250A/ja
Publication of JP2014500250A5 publication Critical patent/JP2014500250A5/ja
Application granted granted Critical
Publication of JP6029591B2 publication Critical patent/JP6029591B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013537902A 2010-11-06 2011-11-07 ナノポリマーをベースとした核酸送達のための組成物および方法 Expired - Fee Related JP6029591B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41086310P 2010-11-06 2010-11-06
US61/410,863 2010-11-06
US41135810P 2010-11-08 2010-11-08
US61/411,358 2010-11-08
PCT/US2011/059558 WO2012061803A2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016080377A Division JP2016164181A (ja) 2010-11-06 2016-04-13 ナノポリマーをベースとした核酸送達のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2014500250A JP2014500250A (ja) 2014-01-09
JP2014500250A5 true JP2014500250A5 (enExample) 2015-02-05
JP6029591B2 JP6029591B2 (ja) 2016-11-24

Family

ID=46025153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537902A Expired - Fee Related JP6029591B2 (ja) 2010-11-06 2011-11-07 ナノポリマーをベースとした核酸送達のための組成物および方法
JP2016080377A Pending JP2016164181A (ja) 2010-11-06 2016-04-13 ナノポリマーをベースとした核酸送達のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016080377A Pending JP2016164181A (ja) 2010-11-06 2016-04-13 ナノポリマーをベースとした核酸送達のための組成物および方法

Country Status (10)

Country Link
US (3) US20130287853A1 (enExample)
EP (1) EP2635261B1 (enExample)
JP (2) JP6029591B2 (enExample)
CN (2) CN103282024A (enExample)
AU (3) AU2011323078B2 (enExample)
CA (1) CA2816999A1 (enExample)
ES (1) ES2763432T3 (enExample)
IL (1) IL226170B (enExample)
MX (1) MX358050B (enExample)
WO (1) WO2012061803A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871247B2 (en) 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
CA2796068C (en) 2010-04-15 2022-07-19 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
EP2635261B1 (en) * 2010-11-06 2019-10-23 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery
MX356877B (es) 2011-04-15 2018-06-19 Marine Polymer Tech Inc Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
CA2968160C (en) * 2016-05-31 2024-01-02 Sachiko Sato Use of n-acetylglucosamine and derivatives thereof to treat muscle disorders
EP3693024A1 (en) * 2019-02-05 2020-08-12 Altona Diagnostics GmbH Control for nucleic acid preparation and/or detection methods
IT202200004574A1 (it) * 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB0126923D0 (en) * 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) * 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
CA2487564A1 (en) * 2004-11-12 2006-05-12 Valorisation Recherche Hscm Folic acid-chitosan-dna nanoparticles
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2068917A2 (en) * 2006-09-22 2009-06-17 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Compositions and methods for chitosan enhanced immune response
KR100882611B1 (ko) * 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
KR20090108723A (ko) * 2007-01-31 2009-10-16 알러간, 인코포레이티드 안 약물 송달을 위한 신규한 생체적합물질 및 이의 제조방법 및 용도
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same
US20100105139A1 (en) * 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
CA2833415A1 (en) * 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
EP2635261B1 (en) * 2010-11-06 2019-10-23 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery

Similar Documents

Publication Publication Date Title
JP2014500250A5 (enExample)
Wong et al. Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment
RU2014122432A (ru) Способ получения липидных наночастиц для доставки лекарственного средства
HK1208161A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
WO2009136763A3 (en) Nanoparticles for penetration of blood-brain barrier
JP2017165748A5 (enExample)
JP2015501791A5 (enExample)
CL2013000347A1 (es) Poblacion de microparticulas que comprenden un corticoesteroide clase b incorporado en una matriz formada por un copolimero de acido lactico y acido glicolico, donde dicho corticoesteroide comprende entre 22% a 28% de las microparticulas; preparacion de liberacion controlada; formulacion; y metodo de fabricacion.
JP2010513363A5 (enExample)
JP2014508752A5 (enExample)
JP2012532992A5 (enExample)
WO2012170372A3 (en) Prna mutlivalent junction domain for use in stable multivalent rna nanoparticles
JP2015520197A5 (enExample)
JP2014514275A5 (enExample)
JP2012526134A5 (enExample)
CA2816999A1 (en) Compositions and methods for nanopolymer-based nucleic acid delivery
IT1393040B1 (it) Processo per la preparazione di sospensioni stabili di nanoparticelle metalliche e sospensioni colloidali stabili cosi' ottenute
JP2013532729A5 (enExample)
WO2010030821A3 (en) Ibuprofen for topical administration
MY165003A (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
Chaudhary et al. Enhancing the bioavailability of mebendazole by integrating the principles solid dispersion and nanocrystal techniques, for safe and effective management of human echinococcosis
JP2015501791A (ja) 新規な遺伝子伝達用組成物
WO2013058482A3 (ko) 표적지향 및 치료가 가능한 다기능성 핵산 기반 항암제, 이의 제조 방법 및 이를 포함하는 항암제 조성물
DOP2015000128A (es) Dispersión sólida con solubilidad mejorada que comprende un derivado de tetrazol como ingrediente activo
JP2014510782A5 (enExample)